Reference/Lee 2017 Reference

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Structural epitope mapping for both clinical antibodies — the benchmark this campaign's GFCC′-face choice is checked against (PD-L1/Note/Epitope choice).